[Rate of complications in acute treatment of stomach ulcer: modification of the incidence by active therapy in placebo-controlled studies].
We evaluated 32 randomized placebo-controlled trials in gastric ulcer patients to determine the ulcer-related complication rate (bleeding, perforation) during short-term therapy. Patients treated with placebo had a significantly greater risk to drop out for ulcer-related complications than patients treated with active drugs (1,2% vs 0%; p less than 0,01), while the number of patients dropping out for other reasons did not differ significantly (8,4% vs 7,3%, p greater than 0,1). Thus, the efficiency of active drug therapy in gastric ulcer episodes is not only reflected by a significantly higher healing rate in 4 to 8 weeks (64,7% vs 41,4%, p less than 0,01) but also by a much lower risk for ulcer-related complications.
Coenen
C
C
Medizinische Klinik der Ruhr-Universität Bochum, St.-Josef-Hospital.
Börsch
G
G
D000897:Anti-Ulcer Agents / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D006801:Humans; D010438:Peptic Ulcer Hemorrhage / Q000517:prevention & control*; D010439:Peptic Ulcer Perforation / Q000517:prevention & control*; D013276:Stomach Ulcer / Q000150:complications / Q000188:drug therapy*; D014945:Wound Healing / Q000187:drug effects*
D000897:Anti-Ulcer Agents
Komplikationsrate während der Akutbehandlung des Magenulkus: Beeinflussung der Inzidenz durch Verumtherapie in plazebokontrollierten Studien.